Qualification of an IFN-γ ELISpot Assay for Monitoring Antigen-Specific T-Cell Responses in Clinical Trials of T-cell-inducing Vaccines
Abstract The IFN-γ ELISpot assay is a sensitive, widely used platform for quantifying antigen-specific T-cell responses and serves as a benchmark assay for immunomonitoring in vaccine trials. Despite its broad adoption, clinical use requires formal qualification to ensure reproducibility, reliability, and fitness for use. However, standardised, qualified ELISpot assays remain scarce for clinical trials in Africa. We present an IFN-γ ELISpot assay for measuring antigen-specific T-cell responses in human PBMCs qualified under Good Clinical Laboratory Practice (GCLP) standards. Assay performance was evaluated using predefined parameters, including linearity, precision, specificity, detection capacity, robustness, and reportable range, across multiple PBMC stimulation conditions. Linearity was assessed across six different cell inputs per well using the CEFSX stimulation. Precision was assessed via the predefined coefficient of variation (CV) threshold of ≤ 35% across the evaluated stimulation conditions. Robustness was assessed using a one-factor-at-a-time approach across different post-thawing and incubation times for the three stimulations. Strong linearity was observed across the donor samples (R2=0.90-0.98). All samples met the precision acceptance criteria across all tested conditions, demonstrating performance consistent with accepted standards in the field. Intermediate precision was similarly robust, with minimal operator-dependent variability and 94.4% of replicate values falling within the predefined acceptance limits. There was no significant effect of different post-thawing and incubation times on the assay output (p-value >0.05), and the assay achieved 100% specificity. Overall, the qualified assay demonstrated strong analytical performance and readiness for immunomonitoring in clinical vaccine trials. Importantly, this work establishes our lab as a GCLP-certified African site for clinical vaccine trial immunomonitoring of IFN-γ ELISpot assays.
Authors
- Alabi Waheed Banjoko (ORCID: https://orcid.org/0000-0002-4089-5748)
- Zaza M. Ndhlovu (ORCID: https://orcid.org/0000-0002-2708-3315)
- Namani Ngema
- Lorraine Tshegofatso Maebele (ORCID: https://orcid.org/0000-0003-0903-6045)
- Crystal A. Mendoza (ORCID: https://orcid.org/0000-0002-5554-4318)
- Mali Mlaba
- Tiza Ng’uni
- Nitalia Naidoo
Institutions
- Ragon Institute of MGH, MIT and Harvard (US)
- Africa Health Research Institute (ZA)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-16
- DOI
- https://doi.org/10.21203/rs.3.rs-11483713/v1
- Primary Topic
- Advanced Biosensing Techniques and Applications
- Type
- preprint
Funders
- Bill and Melinda Gates Foundation